wipe up

WALLABY MEDICAL INTRODUCTION

Wallaby Medical Holding, Inc. ("Wallaby") is a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke. Established in 2015, we currently have over 250 employees located in Laguna Hills, California and Shanghai, China.

We develop and produce some of the most reliable and technologically advanced products supported by proven clinical data. Our commercialized product portfolio includes the Avenir® Coil System, a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance™ Aspiration Catheters for use in the revascularization of patients with acute ischemic stroke, and the Esperance™ Distal Access Catheter for general intravascular usage including neuro.

We market our products in over 60 countries and regions around the world, including the U.S., China, Europe and Japan. In addition, we have a full range of neurovascular interventional products currently under development.

  • 0

    +

    Licensed countries/regions

  • 17

    ,

    000

    +

    Office, R&D and manufacturing

NEWS & EVENTSMORE

Development path

Slide left

2023.02

Wallaby Medical phenox Obtained FDA 510k Clearance for its pRESET Thrombectomy Device

2022.09

Wallaby/phenox announces global launch of the pEGASUS HPC Stent System — the first laser-cut, open-cell stent device with antithrombogenic HPC coating technology

2022.05

Avenir® Plus Coil System Approved by NMPA

2022.04

Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion

2022.03

Esperance™ 6F Aspiration Catheter obtained NMPA approval

2021.12

Setup strategic partnership with Japan Lifeline to achieve a larger scale of development in the Japanese market

2021.11

Esperance™ 5F & 6F Aspiration Catheter obtained FDA 510(k) clearance.

2021.09

Phase 1 of new Shanghai Xingchuang Park facility completed

2021.08

Avenir® Coil System obtained NMPA registration approval and was listed in the Innovative Medical Device Product List, China

MORE

Development path

2023.02

Wallaby Medical phenox Obtained FDA 510k Clearance for its pRESET Thrombectomy Device

2022.09

Wallaby/phenox announces global launch of the pEGASUS HPC Stent System — the first laser-cut, open-cell stent device with antithrombogenic HPC coating technology

2022.05

Avenir® Plus Coil System Approved by NMPA

2022.04

Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion

2022.03

Esperance™ 6F Aspiration Catheter obtained NMPA approval

2021.12

Setup strategic partnership with Japan Lifeline to achieve a larger scale of development in the Japanese market

2021.11

Esperance™ 5F & 6F Aspiration Catheter obtained FDA 510(k) clearance.

2021.09

Phase 1 of new Shanghai Xingchuang Park facility completed

2021.08

Avenir® Coil System obtained NMPA registration approval and was listed in the Innovative Medical Device Product List, China

MORE

Development path

©2022 Wallaby Medical. All Rights Reserved     |  Privacy Statement     Official Wechat

©2022 Wallaby Medical. All Rights Reserved
Privacy Statement
Official Wechat